CureVac Q1 2024 Sales €12.400M Beat €12.030M Estimate
Portfolio Pulse from Benzinga Newsdesk
CureVac reported Q1 2024 sales of €12.400 million, surpassing the estimated €12.030 million.
May 23, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CureVac's Q1 2024 sales of €12.400 million exceeded the estimated €12.030 million, indicating strong performance.
CureVac's better-than-expected sales performance for Q1 2024 is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100